Inhibition of eCIRP Attenuates Inflammation and Gut Injury After Radiation Combined Injury with Sepsis
Medical Sciences · 2026
DOI: 10.3390/medsci14050539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, 2026. Verfasst von Fangming Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immunology and Inflammation, Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA. Hauptthemen laut MEDLINE: Sepsis, Inflammation, RNA-Binding Proteins, Radiation Injuries, Experimental. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIGMS NIH HHS.
Themen: Sepsis
Abstract (Originalsprache)
Background
Radiation-induced sepsis resulting from intestinal inflammation and injury is a severe complication of high-dose radiation exposure. High-dose radiation compromises the integrity of the intestinal lining, causing bacterial translocation, systemic inflammation, and sepsis. Extracellular cold-inducible RNA-binding protein (eCIRP), a damage-associated molecular pattern, plays a pivotal role in the pathogenesis of inflammatory diseases and contributes to organ injury. C23, a small molecular peptide antagonist of eCIRP, has demonstrated anti-inflammatory and organ-protective effects during organ-injury indications. However, its role in radiation-induced inflammation and injury is not known. The objective of this study is to evaluate whether C23 mitigates inflammation and injury, leading to improved survival in a murine model of partial-body irradiation (PBI) combined with sepsis.
Methods
Mice were exposed to 10 Gy PBI, and at 48 h, they were subjected to cecal ligation and puncture (CLP), a well-established model of sepsis. C23 (8 mg/kg body weight [BW]) or vehicle (saline) was administered subcutaneously at 24 h and 48 h after PBI. Blood and intestinal tissue samples were collected 20 h after CLP (i.e., 68 h post-PBI) for various analyses. In another set of mice after PBI–sepsis, intestinal permeability was also assessed. In an additional cohort of mice subjected to the same experimental procedure, 10-day survival was monitored.
Results
Our findings demonstrate that administration of C23 attenuated systemic inflammatory responses, intestinal permeability, intestinal injury, and apoptosis; increased crypt cell proliferation and improved survival after PBI–sepsis.
Conclusions
These results reveal a novel protective role of the eCIRP antagonist, C23, in mitigating PBI–sepsis-induced inflammation and injury and represents a promising therapeutic candidate for the treatment of radiation combined injury with sepsis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Immunology and Inflammation, Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA.
- Departments of Surgery and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY 11030, USA.
ORCID-Profile: Asha Jacob, Max Brenner, Ping Wang
Förderung
- NIAID NIH HHS
- NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Zhang, F., Ma, G., Jin, H., Jacob, A., Brenner, M., & Wang, P. (2026). Inhibition of eCIRP Attenuates Inflammation and Gut Injury After Radiation Combined Injury with Sepsis. Medical Sciences. https://doi.org/10.3390/medsci14050539
Vancouver
Zhang F, Ma G, Jin H, Jacob A, Brenner M, Wang P. Inhibition of eCIRP Attenuates Inflammation and Gut Injury After Radiation Combined Injury with Sepsis. Medical Sciences. 2026. doi:10.3390/medsci14050539
BibTeX
@article{Zhang2026,
author = {Zhang, Fangming and Ma, Gaifeng and Jin, Hui and Jacob, Asha and Brenner, Max and Wang, Ping},
title = {Inhibition of eCIRP Attenuates Inflammation and Gut Injury After Radiation Combined Injury with Sepsis},
journal = {Medical Sciences},
year = {2026},
doi = {10.3390/medsci14050539}
}
EUVIMED